BEVERLY, Mass., Oct. 19, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that data recently presented by the Company at the American Association for Cancer Research (AACR) along with other data developed by the Company indicate that Kevetrin is selectively targeting very specific anti-tumor pathways, such as AKT and p38 MAP kinase. The data presented at the AACR showed that Kevetrin was less cytotoxic than paclitaxel, cisplatin and 5FU while having better anti-tumor activity in two multi-drug resistant lung cancer cell lines. This indicates that Kevetrin is not acting primarily as a cytotoxic agent but may be targeting specific components of the signal transduction pathway, such as AKT and p38 MAP kinase. The Company is continuing to explore other potential targets.

Other data developed by the Company indicate that Kevetrin has potent anti-tumor activity in one cell line (MDA-MB–231) despite only partially inhibiting AKT in that cell line.

...

Stocks are lower as a weaker U.S. dollar help lift commodity prices and Johnson & Johnson’s third-quarter sales figures disappointed investors

Stocks fell on Tuesday after disappointing quarterly sales figures from economic bellwether Johnson & Johnson (NYSE: JNJ) sparked worries about consumer spending, offsetting a lift from higher commodity prices.

The Nasdaq gave up its initial gains at the open.

The Dow Jones industrial average was down 53.66 points, or 0.54 percent, at 9,832.14. The Standard & Poor’s 500 Index was down 7.19 points, or 0.67 percent, at 1,069.00. The Nasdaq Composite Index was down 5.16 points, or 0.24 percent, at 2,133.98.

Yesterday’s Top Performing Small Cap Stock:

GWS Technologies, Inc, (OTC BB: GWSC) was a SmallCapVoice.com top performer yesterday closing up over 8% on trading volume of 19,747 shares.

GWS stands for GreenWindSolar. GWSC is a renewable energy technology company developing and marketing solar and wind-powered renewable energy products and solutions. Our

...

Kevetrin(TM) Shows Excellent Activity in Animal Models of Drug Resistant Lung Cancer With Less Cytotoxicity Than Paclitaxel

Cellceutix of Beverly, MA, to Pursue Development for Drug-Resistant Lung Cancer

BEVERLY, Mass., Oct. 13, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that it presented a poster and its Chief Scientific Officer, Dr. Krishna Menon, was one of only four individuals selected to participate in an expert panel discussion of the abstract at the American Association for Cancer Research (AACR) meeting “Frontiers in Basic Cancer Research” in Boston, MA on October 10, 2009. The Company’s poster describes in vitro and in vivo research on its lead compound, Kevetrin(TM), which is being developed for drug resistant cancers. The three day AACR meeting featured presentations on the latest advances in basic cancer research from around the world. The AACR issued a press release on October 10, 2009 which featured the abstract submitted

...

On Friday April 24, 2009, Micromet Inc. (MITI) held a briefing for investors and financial analysts in New York to provide an update on the company's drug development pipeline.A key highlight of the presentation was the announcement that a rapid path to market has been identified in acute lymphoblastic leukemia (ALL) for the company's lead drug candidate BiTE antibody blinatumomab (MT103) with a registration trial planned for 2010. This was in addition to a dose escalation study which is currently underway of blinatumomab for non Hodgkin's lymphoma, with final results expected to be reported at the American Society of Hematology meeting in December.MITI also provided an update on MT110, which is currently in a phase 1 dose-escalating clinical trial in patients with lung or gastrointestinal cancer. In addition, pre-clinical data for the company's EGFR BiTE Antibody, presented at the recent annual meeting of the ...